Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas

Authors

Jonathan Thouvenin
Omar Alhalabi
Maria Carlo
Lucia Carril-Ajuria
Laure Hirsch
Nieves Martinez-Chanza
Sylvie Négrier
Luca Campedel
Dylan Martini
Delphine Borchiellini
Jad Chahoud
Massimo Lodi
Philippe Barthélémy
Elshad Hasanov
Andrew W Hahn
Thierry Gil
Srinivas R Viswanathan
Ziad Bakouny
Pavlos Msaouel
Mehmet Asim Bilen
Toni K Choueiri
Laurence Albiges
Nizar M Tannir
Gabriel G Malouf

Publication Date

12-9-2022

Journal

The Oncologist

DOI

10.1093/oncolo/oyac158

PMID

35979929

PMCID

PMC10249266

PubMedCentral® Posted Date

8-18-2022

PubMedCentral® Full Text Version

Post-print

Abstract

Background: MiT family translocation renal cell carcinoma (TRCC) is a rare and aggressive subgroup of renal cell carcinoma harboring high expression of c-MET. While TRCC response rates to VEGF receptor tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors are limited, efficacy of cabozantinib (a VEGFR, MET, and AXL inhibitor) in this subgroup is unclear.

Methods: We performed a multicenter, retrospective, international cohort study of patients with TRCC treated with cabozantinib. The main objectives were to estimate response rate according to RECIST 1.1 and to analyze progression-free survival (PFS) and overall survival (OS).

Results: Fifty-two patients with metastatic TRCC treated in the participating centers and evaluable for response were included. Median age at metastatic diagnosis was 40 years (IQR 28.5-53). Patients' IMDC risk groups at diagnosis were favorable (9/52), intermediate (35/52), and poor (8/52). Eleven (21.2%) patients received cabozantinib as frontline therapy, 15 (28.8%) at second line, and 26 (50%) at third line and beyond. The proportion of patients who achieved an objective response was 17.3%, including 2 complete responses and 7 partial responses. For 26 (50%) patients, stable disease was the best response. With a median follow-up of 25.1 months (IQR 12.6-39), median PFS was 6.8 months (95%CI 4.6-16.3) and median OS was 18.3 months (95%CI 17.0-30.6). No difference of response was identified according to fusion transcript features.

Conclusion: This real-world study provides evidence of the activity of cabozantinib in TRCC, with more durable responses than those observed historically with other VEGFR-TKIs or ICIs.

Keywords

Adult, Humans, Middle Aged, Carcinoma, Renal Cell, Cohort Studies, Kidney Neoplasms, Retrospective Studies, MiT family translocation renal cell carcinoma, cabozantinib, non-clear cell renal cell carcinoma

Published Open-Access

yes

Recommended Citation

Thouvenin, Jonathan; Alhalabi, Omar; Carlo, Maria; et al., "Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas" (2022). Faculty, Staff and Student Publications. 4855.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4855